 | 
|
| |
|
Titel: Sällsynta mutationer leder till framtidens behandling [summary] (serie: Tema demens) 2009 nr 20 sid 1396-400
|
Summary:
The identification of disease-causing mutations in Alzheimer’s disease has greatly contributed to our understanding of the pathogenesis. Based on this knowledge, a number of therapeutic strategies are under development, most of which are aimed at lowering the amount of Abpeptides in the affected brain. Due to intense research efforts and massive investments at universities and in the pharmaceutical industry, the future perspectives for Alzheimer patients have never looked brighter.
Martin Ingelsson, Hans Basun, Frida Ekholm Pettersson, Lena Kilander, Lars N G Nilsson, Lars Lannfelt
Correspondence: Lars Lannfelt, Uppsala universitet, Institutionen för Folkhälsa/Geriatrik
Dag Hammarskjölds väg 14B, SE-751 85 Uppsala, Sweden
lars.lannfelt@pubcare.uu.se
Referenser:
1.SBU. Demenssjukdomar. SBU rapport 2006;172 (91-87890-99-2):
2.Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003;51:937-944.
3.Wimo A, Winblad B, Aguero-Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord. 2003;17:63-67.
4.Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology. 2000;55:1158-1166.
5.Sjögren T, Sjögren H, Lindgren AG. Morbus Alzheimer and morbus Pick; a genetic, clinical and patho-anatomical study. Acta Psychiatr Neurol Scand Suppl. 1952;82:1-152.
6.Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704-706.
7.Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992;1:345-347.
8.Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, et al. Excessive production of amyloid -protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA. 1994;91:11993-11997.
9.Johnston J, Cowburn RF, Norgren S, Wiehager B, Venizelos N, Winblad B, et al. Increased -amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP 670/671 mutation. FEBS Lett. 1994;354:274-278.
10.Lannfelt L, Bogdanovic N, Appelgren H, Axelman K, Lilius L, Hansson G, et al. Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family. Neurosci Lett. 1994;168:254-256.
11.Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
12.Lannfelt L, Lilius L, Nastase M, Viitanen M, Fratiglioni L, Eggertsen G, et al. Lack of association between apolipoprotein E allele µ4 and sporadic Alzheimer's disease. Neurosci Lett. 1994;169:175-178.
13.Nilsson LN, Arendash GW, Leighty RE, Costa DA, Low MA, Garcia MF, et al. Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiol Aging. 2004;25:1153-1167.
14.Basun H, Bogdanovic N, Ingelsson M, Almkvist O, Naslund J, Axelman K, et al. Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol. 2008;65:499-505.
15.Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem. 2007;103:334-345.
16.Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, Nilsson LN. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging. 2006;27:67-77.
17.Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The "Arctic" (E693G) mutation in the A region of APP causes Alzheimer's disease by increasing A protofibril formation. Nat Neurosci. 2001;4:887-893.
18.Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, et al. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol. 2005;58:147-150.
19.Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008;7:779-786.
20.Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372:207-215.
21.Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547-554.
22.Gilman S, Koller M, Black R, Jenkins L, Griffith S, Fox N, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553-1562.
23.Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216-223.
24.Ingelsson M, Fukumoto H, Newell K, Growdon JH, Hedley-Whyte TE, Albert MS, et al. Early Abeta accumulation and progressive synaptic loss, gliosis and tangle formation in AD brain. Neurology. 2004;62:925-931.
25.Cummings JL. Toward a molecular neuropsychiatry of neurodegenerative diseases. Ann Neurol. 2003;54:147-154.
26.Lewis J, Dickson D, Lin W, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487-1491.
 1396 |
 1397 |
 1398 |
 1399 |
 1400 |